Guardian Bio

Guardian Bio is a biotech company in Boston, United States, founded in 2022. It has raised $598K across 2 rounds, most recently a $98K Grant in November 2023.

Dendritic cell-based platform for cancer therapy

Employees
1–10
Founded
2022
Total Funding
$598K
Last Round
$98K GrantNov 2023
Rounds
2

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 2 funding rounds and 2 investors for this company. The full record is or through the API.

About

Your immune system is your body’s best weapon and defense against cancer. It is only when it is overcome that cancer develops into full blown disease. Dendritic cells sit at the helm of the immune system, directing and dictating immune responses. Data has shown dendritic cells are often dysfunctional in cancer patients, and that this dysfunction is a bottleneck for other therapies. Guardian Bio’s approach is focused on creating a dendritic cell-based product which drives anti-tumor activity through activating the killers of the immune system AND training them against multiple cancer targets. We take stem cells from cancer patients, turn them into specific therapeutic dendritic cells specially trained against that patient’s tumor, and re-introduce them back into the body. Our therapeutic dendritic cells revitalize the killers of the immune system and give them the kickstart they need to fight - and win - against cancer.

Summary

It lists 1–10 employees. It has raised $598K in total across 2 rounds, most recently a $98K Grant round in Nov 2023. Investors include Massachusetts Life Sciences Center and Y Combinator.

Funding History

Data from Indexed.vcUpdated
GrantNov 2023
$98K

Sign up to see all 2 events

Funding: Seed through Grant. Amounts, valuations, and investors where available.

Investors

Similar Companies

BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech, Oncology
Corporate RoundTotal funding$2.8BJan 2020
Paratek PharmaceuticalsAcquired

Paratek Pharmaceuticals develops and delivers innovative treatments for serious infectious diseas...

Boston, United States201–500Biotech, Healthcare
ConvertibleTotal funding$1.8BApr 2018
Sana BiotechnologyIPO

Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...

Seattle, United States201–500Biotech, Healthcare
Series DTotal funding$1.4BJun 2020
Abogen Biosciences

Abogen Biosciences develops RNA therapeutics using integrated mRNA design, lipid nanoparticle del...

Suzhou, China201–500Biotech, Drug Discovery
Extension RoundTotal funding$1.2BNov 2021
Alnylam PharmaceuticalsIPO

Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...

Cambridge, United States1001–5000Biotech, Genomics
Corporate RoundTotal funding$1.0BApr 2020
Tiantan Biological / China Biologic (泰邦生物集团)

China's leading blood products manufacturer

Beijing, China1001–5000Biotech, Healthcare
Growth EquityTotal funding$5.1BAug 2022

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Guardian Bio on Indexed.vc
<a href="https://indexed.vc/companies/guardian-bio"><img src="https://indexed.vc/api/badge/company/guardian-bio" alt="Guardian Bio on Indexed.vc" width="260" height="76" /></a>